Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and/or Myocarditis in Patients With T-Cell Lymphoma

Mogamulizumab is being increasingly prescribed for the treatment of T-cell lymphomas (MF/SS/ATLL). We conducted a retrospective cohort study to identify muscular immune-related adverse events (irAEs) associated with mogamulizumab in patients with T-cell lymphoma followed at Dana-Farber Cancer Instit...

Descripción completa

Detalles Bibliográficos
Autores principales: Virgen, Cesar A, Sparks, Jeffrey A, Nohria, Anju, O’Hare, Meabh J, Goyal, Amrita, Said, Jordan T, Tawa, Marianne, LeBoeuf, Nicole R, Kupper, Thomas S, Fisher, David C, Larocca, Cecilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400128/
https://www.ncbi.nlm.nih.gov/pubmed/37285523
http://dx.doi.org/10.1093/oncolo/oyad155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400128/
https://www.ncbi.nlm.nih.gov/pubmed/37285523
http://dx.doi.org/10.1093/oncolo/oyad155

Ejemplares similares